The <i>Petasites hybridus</i> CO<sub>2</sub> Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro
The coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), has spread worldwide, affecting over 250 million people and resulting in over five million deaths. Antivirals that are effective are still limited. The antiviral activities of the <i>Petasites hybdridus</i&...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/1/106 |
| _version_ | 1797489743695446016 |
|---|---|
| author | Lorena Urda Matthias Heinrich Kreuter Jürgen Drewe Georg Boonen Veronika Butterweck Thomas Klimkait |
| author_facet | Lorena Urda Matthias Heinrich Kreuter Jürgen Drewe Georg Boonen Veronika Butterweck Thomas Klimkait |
| author_sort | Lorena Urda |
| collection | DOAJ |
| description | The coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), has spread worldwide, affecting over 250 million people and resulting in over five million deaths. Antivirals that are effective are still limited. The antiviral activities of the <i>Petasites hybdridus</i> CO<sub>2</sub> extract Ze 339 were previously reported. Thus, to assess the anti-SARS-CoV-2 activity of Ze 339 as well as isopetasin and neopetasin as major active compounds, a CPE and plaque reduction assay in Vero E6 cells was used for viral output. Antiviral effects were tested using the original virus (Wuhan) and the Delta variant of SARS-CoV-2. The antiviral drug remdesivir was used as control. Pre-treatment with Ze 339 in SARS-CoV-2-infected Vero E6 cells with either virus variant significantly inhibited virus replication with IC<sub>50</sub> values of 0.10 and 0.40 μg/mL, respectively. The IC<sub>50</sub> values obtained for isopetasin ranged between 0.37 and 0.88 μM for both virus variants, and that of remdesivir ranged between 1.53 and 2.37 μM. In conclusion, Ze 339 as well as the petasins potently inhibited SARS-CoV-2 replication in vitro of the Wuhan and Delta variants. Since time is of essence in finding effective treatments, clinical studies will have to demonstrate if Ze339 can become a therapeutic option to treat SARS-CoV-2 infections. |
| first_indexed | 2024-03-10T00:21:01Z |
| format | Article |
| id | doaj.art-98e9e24048f3488d921e4e78a0049821 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T00:21:01Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-98e9e24048f3488d921e4e78a00498212023-11-23T15:42:19ZengMDPI AGViruses1999-49152022-01-0114110610.3390/v14010106The <i>Petasites hybridus</i> CO<sub>2</sub> Extract (Ze 339) Blocks SARS-CoV-2 Replication In VitroLorena Urda0Matthias Heinrich Kreuter1Jürgen Drewe2Georg Boonen3Veronika Butterweck4Thomas Klimkait5Department Biomedicine, University of Basel, Petersplatz 10, 4051 Basel, SwitzerlandMedical Department, Max Zeller & Söhne AG, Seeblickstrasse 4, 8590 Romanshorn, SwitzerlandMedical Department, Max Zeller & Söhne AG, Seeblickstrasse 4, 8590 Romanshorn, SwitzerlandMedical Department, Max Zeller & Söhne AG, Seeblickstrasse 4, 8590 Romanshorn, SwitzerlandMedical Department, Max Zeller & Söhne AG, Seeblickstrasse 4, 8590 Romanshorn, SwitzerlandDepartment Biomedicine, University of Basel, Petersplatz 10, 4051 Basel, SwitzerlandThe coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), has spread worldwide, affecting over 250 million people and resulting in over five million deaths. Antivirals that are effective are still limited. The antiviral activities of the <i>Petasites hybdridus</i> CO<sub>2</sub> extract Ze 339 were previously reported. Thus, to assess the anti-SARS-CoV-2 activity of Ze 339 as well as isopetasin and neopetasin as major active compounds, a CPE and plaque reduction assay in Vero E6 cells was used for viral output. Antiviral effects were tested using the original virus (Wuhan) and the Delta variant of SARS-CoV-2. The antiviral drug remdesivir was used as control. Pre-treatment with Ze 339 in SARS-CoV-2-infected Vero E6 cells with either virus variant significantly inhibited virus replication with IC<sub>50</sub> values of 0.10 and 0.40 μg/mL, respectively. The IC<sub>50</sub> values obtained for isopetasin ranged between 0.37 and 0.88 μM for both virus variants, and that of remdesivir ranged between 1.53 and 2.37 μM. In conclusion, Ze 339 as well as the petasins potently inhibited SARS-CoV-2 replication in vitro of the Wuhan and Delta variants. Since time is of essence in finding effective treatments, clinical studies will have to demonstrate if Ze339 can become a therapeutic option to treat SARS-CoV-2 infections.https://www.mdpi.com/1999-4915/14/1/106SARS-CoV-2COVID-19anti-COVID-19antiviralDelta variant<i>Petasites hybridus</i> |
| spellingShingle | Lorena Urda Matthias Heinrich Kreuter Jürgen Drewe Georg Boonen Veronika Butterweck Thomas Klimkait The <i>Petasites hybridus</i> CO<sub>2</sub> Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro Viruses SARS-CoV-2 COVID-19 anti-COVID-19 antiviral Delta variant <i>Petasites hybridus</i> |
| title | The <i>Petasites hybridus</i> CO<sub>2</sub> Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro |
| title_full | The <i>Petasites hybridus</i> CO<sub>2</sub> Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro |
| title_fullStr | The <i>Petasites hybridus</i> CO<sub>2</sub> Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro |
| title_full_unstemmed | The <i>Petasites hybridus</i> CO<sub>2</sub> Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro |
| title_short | The <i>Petasites hybridus</i> CO<sub>2</sub> Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro |
| title_sort | i petasites hybridus i co sub 2 sub extract ze 339 blocks sars cov 2 replication in vitro |
| topic | SARS-CoV-2 COVID-19 anti-COVID-19 antiviral Delta variant <i>Petasites hybridus</i> |
| url | https://www.mdpi.com/1999-4915/14/1/106 |
| work_keys_str_mv | AT lorenaurda theipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT matthiasheinrichkreuter theipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT jurgendrewe theipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT georgboonen theipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT veronikabutterweck theipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT thomasklimkait theipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT lorenaurda ipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT matthiasheinrichkreuter ipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT jurgendrewe ipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT georgboonen ipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT veronikabutterweck ipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro AT thomasklimkait ipetasiteshybridusicosub2subextractze339blockssarscov2replicationinvitro |